Home-based heart rehabilitation by telehealth for chronic heart failure
Compares home-based remote heart rehabilitation with standard in-person rehabilitation in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Effectiveness of a Cardiac Telerehabilitation Program in Chronic Heart Failure
Key facts
- Where
- Salerno, ItalySee the site
Where in Italy
- Hospital University San Giovanni di Dio e Ruggi d'AragonaSalerno, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Salerno
- Trial code
- NCT07023536
- Record updated
- 11 March 2026
- Original description
The goal of this observational study is to evaluate whether a home-based cardiac tele-rehabilitation program can improve functional capacity in adults (18 years and older) with chronic heart failure. The main questions it aims to answer are:Read full original descriptionShow less
Evaluation of the Effectiveness of a Cardiac Telerehabilitation Program in Chronic Heart Failure
The goal of this observational study is to evaluate whether a home-based cardiac tele-rehabilitation program can improve functional capacity in adults (18 years and older) with chronic heart failure. The main questions it aims to answer are:
Does tele-rehabilitation improve peak oxygen uptake (VO₂ max) compared to standard in-hospital rehabilitation? Does it improve cardiac function, exercise tolerance, biochemical markers, and quality of life? Are functional gains maintained at 24 weeks? Researchers will compare patients who opt for tele-rehabilitation using wearable devices and a remote monitoring platform with those undergoing standard in-person rehabilitation. Participants will follow an 8-week individualized training program and undergo assessments at baseline, 4, 8, 16, and 24 weeks.
Inclusion: Age ≥ 18 years; Diagnosis of chronic heart failure for at least 6 months, with stable optimal medical therapy for at least 1 month; New York Heart Association (NYHA) functional class I, II, or III; Hospitalization or outpatient visit requiring intravenous therapy (diuretics, vasodilators, or inotropes) within the past 12 months; Ability to provide informed consent or presence of a legal representative; Digital literacy of the patient and/or caregiver.
Exclusion: NYHA class IV heart failure; Other serious illnesses significantly limiting life expectancy (e.g., end-stage cancer, advanced pulmonary disease); Severe renal insufficiency (eGFR <30 ml/min/1.73 m²) or on dialysis; Age < 18 years; Pregnancy.